Analysis finds pharma-funded ties among many patient and consumer voices on FDA panels
An analysis found that nearly 40% of FDA advisory committee meetings over a 20-year span included a patient or consumer representative with active ties to an advocacy group funded by drugmakers. The finding points to possible conflicts of interest in the committees that advise the FDA.
Across a 20-year period, the study looked at meetings of FDA advisory committees. It centered on the patient and consumer representatives who sit on those panels.
In close to two-fifths of those meetings, at least one representative had current connections to an advocacy organization that receives drug industry funding. The finding suggests potential conflicts of interest on the panels that counsel the FDA.
The finding may affect public trust in FDA advisory panels, especially among patients who rely on their recommendations. If patient and consumer voices are seen as aligned with industry funders, confidence in the review process could weaken. Drugmakers, advocacy groups, and regulators may face pressure to clarify funding relationships. Patients and the public could be most affected if trust in the committees erodes.